西藏诺迪康药业股份有限公司差异化分红事项详解：投资者需关注的关键点
背景信息
西藏诺迪康药业股份有限公司（简称“西藏药业”）近日披露了2025年度利润分配中涉及的差异化分红事项，并由泰和泰律师事务所出具了相关法律意见书。此次差异化分红方案，与公司回购股份相关，涉及资金分配、股本结构调整等多项关键内容，具有一定的市场敏感性，值得投资者重点关注。
差异化分红方案核心要点
- 分红基数调整：本次分红以实施权益分派股权登记日总股本扣除回购专用证券账户中的股份为基数。即，回购专用证券账户4,000,058股不参与本次利润分配，实际分配股本为318,319,138股。
- 分红金额及比例：2025年度公司计划以合并报表中归属于上市公司股东净利润的60%进行现金分红，总额为562,810,776.57元。此前已分红283,963,211.68元，本次实际派发278,847,564.89元（含税），每股派发现金0.876元（含税）。
- 总股本变化：截至法律意见书出具日，公司总股本为322,319,196股，回购专用证券账户股份占总股本1.24%。
- 回购股份用途：回购股份计划用于实施股权激励或员工持股计划，回购价格不超过55元/股，总资金不超过2亿元。
重要法律依据与合规性
- 律师意见明确依据《公司法》《证券法》及《公司章程》，回购专用账户股份不享有利润分配权。
- 上海证券交易所相关指引亦规定，已回购至专用账户的股份不参与分配，需进行差异化权益分派特殊除权除息处理。
差异化除权除息方案及影响
- 除权除息价格计算：
- 实际分派计算：除权（息）参考价格 = （前收盘价格 – 实际分派现金红利）/ (1+流通股份变动比例)。以前收盘价42.32元计，除权除息参考价为41.444元/股。
- 虚拟分派计算：虚拟分派现金红利为0.8651元/股，对应参考价41.4549元/股。
- 二者差额仅为0.0109元，影响绝对值约为0.03%，低于1%，对股价影响极小。
投资者需关注的关键事项
- 回购股份不参与分红：公司回购专用账户持有的4,000,058股A股不参与本次利润分配，未来如有回购股份注销或用于激励计划，相关股本及分红方案可能进一步变化。
- 分红总额保持不变：如因可转债、回购或股权激励等导致总股本变动，公司将维持现金派发总额不变，调整每股派发金额。
- 合规性保障：本次差异化分红事项已获律师出具无异议法律意见，未发现损害公司和股东利益的情形。
潜在市场影响及展望
此次差异化分红事项虽对除权除息价格影响有限，但显示公司积极回购股份、实施股权激励，有助于提升公司管理层和员工积极性，增强投资者信心。投资者应关注公司后续回购计划推进及股权激励实施进展，相关变动有可能对公司未来分红政策和股价产生影响。
免责声明：本报道仅供投资者参考，不构成任何投资建议。投资者应结合自身风险偏好及市场情况，谨慎决策。信息来源于西藏诺迪康药业股份有限公司公告及法律意见书，实际以公司公告为准。
English Version
Detailed Analysis of Tibet Rhodiola Pharmaceutical Co., Ltd. Differential Dividend: Key Points for Investors
Background
Tibet Rhodiola Pharmaceutical Co., Ltd. (“Tibet Pharma”) recently disclosed a differential dividend plan for its 2025 annual profit distribution, with a legal opinion issued by Tahota Law Firm. The plan is closely tied to the company’s share buyback program, involving adjustments to profit allocation and share capital structure, which are potentially market-sensitive and merit investor attention.
Main Points of the Differential Dividend Plan
- Adjusted Dividend Base: The dividend will be distributed to the total share capital on the record date, minus shares held in the repurchase dedicated securities account. 4,000,058 shares in the buyback account are excluded, leaving 318,319,138 shares eligible for distribution.
- Dividend Amount and Ratio: For FY2025, the company plans to distribute 60% of the net profit attributable to shareholders as cash dividends, totaling RMB 562,810,776.57. After deducting RMB 283,963,211.68 already distributed, the current dividend is RMB 278,847,564.89 (tax inclusive), or RMB 0.876 per share.
- Total Share Capital Change: As of the legal opinion date, total shares stand at 322,319,196, with repurchased shares accounting for 1.24%.
- Buyback Purpose: Shares are to be used for employee incentive or shareholding plans, with a buyback price not exceeding RMB 55/share and a total buyback fund not exceeding RMB 200 million.
Legal Basis & Compliance
- The legal opinion confirms compliance with the Company Law, Securities Law, and company articles: shares in the buyback account do not enjoy dividend rights.
- SSE regulations also require that repurchased shares in dedicated accounts do not participate in distribution and must be handled with special ex-rights/ex-dividend treatment.
Ex-rights/Ex-dividend Plan and Impact
- Ex-rights/Ex-dividend Price Calculation:
- Actual distribution: Ex-rights price = (Last closing price – actual dividend per share)/(1 + change in tradable shares). With last close at RMB 42.32, the ex-rights price is RMB 41.444/share.
- Virtual distribution: Virtual dividend per share is RMB 0.8651, ex-rights price is RMB 41.4549/share.
- The difference is only RMB 0.0109, or about 0.03%—a negligible impact on share price.
Key Issues for Investors
- Repurchased Shares Excluded from Dividend: The 4,000,058 shares in the buyback account are excluded from this distribution. Future cancellation or use of these shares for incentive plans may affect future capital and dividend policies.
- Total Dividend Remains Unchanged: If total shares change due to convertible bonds, buybacks, or incentive plans, the total cash dividend remains unchanged, but per-share payouts will be adjusted accordingly.
- Compliance Assurance: The legal opinion confirms no violation of laws or shareholder interests.
Potential Market Impact and Outlook
While this differential dividend has little impact on the ex-rights price, it demonstrates the company’s commitment to share buybacks and employee incentives—potentially boosting management motivation and investor confidence. Investors should track future buyback and incentive plan developments, as these may affect future dividend policies and share price.
Disclaimer: This report is for investor reference only and does not constitute investment advice. Investors should make prudent decisions based on their risk preferences and actual market conditions. Information is based on Tibet Rhodiola Pharmaceutical’s public disclosures and the legal opinion; official announcements shall prevail.
